MicroRNAs as Diagnostic and Predictive Biomarkers for Acute Graft Versus Host Disease

Withdrawn before enrolling

Conditions studied: Acute GVH Disease

In brief

The goal of this research proposal is to identify a miRNA expression profile as a biomarker to diagnose and predict acute graft versus host disease (aGVHD) in patients who undergo allogeneic transplantation. This biomarker, once identified, will need validation in larger cohorts.

Key facts

Study ID

NCT02917148

Run by

Northwell Health

People needed

0

Starts

2016-09-01

Expected to finish

2018-09-01

Last updated by the study team

2017-10-11

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients undergoing fully matched allogeneic PBCSC and bone marrow transplantation who present with clinical signs and symptoms of grade II- IV aGVHD within 100 days after transplantation as defined by skin, GI, and/or liver involvement that are confirmed by biopsy, regardless of age
• Patients undergoing a matched, unrelated donor (8/8) or matched, related donor transplant (6/6)
• Allogeneic transplant is from donor's peripheral blood stem cells or bone marrow transplant
• Patients who develop grade II-IV aGVHD

You may not qualify if…

• Patients who receive transplants from incompletely matched donors
• Patients who receive T cell depleted transplants
• Patients who receive haplo-identical transplants
• Pregnant Patients

Where it is running

• Monter Cancer Center — Lake Success, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.